McKesson Corporation (NYSE:MCK) is one of the stocks on Jim Cramer’s recent game plan. Cramer highlighted what usually happens when the stock reports, as he said:
Oh, and I have a wild card for you. The president’s on the warpath against all sorts of companies in the healthcare chain. You know, I mean, we saw them this week on Humana, on UnitedHealth, on CVS. Well, when you get doctors and drug execs and health insurers offline to ask who makes the most and does the least, they always say it’s the drug middlemen, the distributors between the drug companies and the consumer. When I ask hey, is it McKesson? They don’t say a thing, but they wink. I’ll tell you this: when this company reports, its stock usually flies. I bet you history repeats itself.
A stock market data. Photo by AlphaTradeZone on Pexels
McKesson Corporation (NYSE:MCK) distributes pharmaceutical drugs and medical-surgical supplies to pharmacies, hospitals, and physician offices. The company also provides healthcare technology and business services. Cramer mentioned the company during the episode aired on May 14, 2025, and said:
These stocks, namely Cardinal Health, Cencora, and McKesson, are seemingly perpetual residents on the new high list. Over the long haul, they’re some of the best performers out there, and they’ve done great this year, as is pretty much always the case. And yet, doesn’t it always feel like the drug distributors are just one bad day away from falling apart… The last quarter from the major drug distributors came from McKesson, and that was last Thursday night, which delivered yet another very strong set of numbers… Like the others. McKesson had a top-line miss, in this case, actually a pretty sizable one, but still delivered a significant earnings beat, and gave a higher-than-expected full-year earnings forecast in a vacuum.
I think the McKesson quarter was strong enough to spark a nice rally for the stock last Friday. But we don’t live in a vacuum, do we?… The big negative development for the drug distributors came midweek when Politico reported that President Trump would be reviving an effort to dramatically cut drug costs by adopting what’s known as the Most-Favored-Nation pricing for Medicare…
As a result, all the drug distributors are either flat or slightly lower this week… so that’s the conundrum with these middlemen, Cardinal, Cencora, and McKesson are all doing incredibly well, but like I said before, there always seems to be a threat that they could be regulated out of existence.
It is worth noting that McKesson Corporation’s (NYSE:MCK) stock has gained 22% since the above comment was aired.
While we acknowledge the risk and potential of MCK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MCK and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
Hedge Fund Resource Center